Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical Products Administration (NMPA) in China has approved a clinical trial filing for its bispecific antibody (BsAb) JS207. The drug is under development to target PD-1 and VEGF for the treatment of advanced malignant tumors.
Pre-Clinical Trials Show Promising Results
Pre-clinical in vivo pharmacological trials have demonstrated that JS207 possesses significant anti-tumor effects and exhibits a dose-dependent response. Moreover, the drug has shown good tolerance in animal models. These results suggest that JS207 has the potential to be an effective treatment option for patients with advanced malignant tumors.
Global Novelty of JS207
As of the announcement, there are no similar products approved for marketing worldwide, highlighting the innovative nature of JS207. The approval of the clinical trial by the NMPA marks a significant step forward in the development of this potentially groundbreaking therapy.-Fineline Info & Tech
